Insider Buying: NewGenIvf Group (NASDAQ:NIVF) Director Acquires $2,500,000.00 in Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung bought 2,500,000 shares of the company’s stock in a transaction on Monday, July 27th. The shares were acquired at an average price of $1.00 per share, with a total value of $2,500,000.00. Following the transaction, the director directly owned 3,722,223 shares in the company, valued at approximately $3,722,223. The trade was a 204.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Kong Yiu Cheung also recently made the following trade(s):

• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The stock was purchased at an average cost of $1.33 per share, with a total value of $665,000.00.

NewGenIvf Group Trading Down 1.4%

Shares of NIVF stock opened at $1.33 on Wednesday. The firm has a fifty day moving average of $2.96 and a 200-day moving average of $11.34. NewGenIvf Group Limited has a 12-month low of $1.15 and a 12-month high of $1,539.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on NIVF shares. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen raised NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, NewGenIvf Group presently has a consensus rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.